Dixon Hubard Feinour & Brown Inc. VA boosted its stake in Zoetis Inc. (NYSE:ZTS) by 2.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,265 shares of the company’s stock after buying an additional 330 shares during the period. Dixon Hubard Feinour & Brown Inc. VA’s holdings in Zoetis were worth $765,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Assetmark Inc. raised its position in Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares during the period. Guardian Life Insurance Co. of America raised its position in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd purchased a new position in Zoetis during the first quarter valued at approximately $111,000. Advisory Services Network LLC purchased a new position in Zoetis during the first quarter valued at approximately $112,000. Finally, First Interstate Bank raised its position in Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after buying an additional 76 shares during the period. Hedge funds and other institutional investors own 95.10% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) traded down 0.44% during mid-day trading on Monday, hitting $63.07. 1,695,813 shares of the stock traded hands. The stock has a market cap of $30.95 billion, a PE ratio of 36.67 and a beta of 1.03. The company has a 50 day moving average of $62.00 and a 200-day moving average of $56.13. Zoetis Inc. has a 12-month low of $46.86 and a 12-month high of $63.85.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 4th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.05. The business had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.48 EPS. Equities research analysts forecast that Zoetis Inc. will post $2.33 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Thursday, June 15th will be issued a $0.105 dividend. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.67%. Zoetis’s payout ratio is 24.42%.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/07/17/zoetis-inc-zts-shares-bought-by-dixon-hubard-feinour-brown-inc-va.html.
Several research analysts recently commented on the stock. Hilliard Lyons assumed coverage on shares of Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective for the company. Credit Suisse Group boosted their price objective on shares of Zoetis from $61.00 to $67.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 24th. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a research note on Wednesday, May 10th. Cowen and Company reiterated a “buy” rating and set a $70.00 price objective on shares of Zoetis in a research note on Monday. Finally, BMO Capital Markets lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $64.00 to $65.00 in a research note on Tuesday, June 13th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $63.11.
In other news, insider Catherine A. Knupp sold 5,785 shares of Zoetis stock in a transaction on Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the transaction, the insider now directly owns 24,415 shares of the company’s stock, valued at approximately $1,468,806.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.31% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.